Processa PharmaceuticalsPCSA
13F holders, Q3 2025 (September 30)14holders +1
7new positions
6sold out
$0.19avg. 13F price*
At the end of Q3 2025, 14 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, up 1 from Q2 2025. 7 opened new positions and 6 sold out. The largest holders were Stonepine Capital Management, LLC ($198K), Geode Capital Management, LLC ($58K) and Vanguard Group Inc. ($55K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $220K |
| Exits | 6 | $39K |
All 13F filers, Q2 2025 → Q3 2025: 1,662,395 shares bought and 254,107 shares sold, net +1,408,288 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Stonepine Capital Management, LLC | 0.16% | New | 1,030,200 | $198K |
| Geode Capital Management, LLC | 0.00% | Add +499.7% | 303,304 | $58K |
| Vanguard Group Inc. | 0.00% | Add +1079.6% | 288,212 | $55K |
| Virtu Financial LLC | 0.00% | Reduce -61.0% | 40,843 | $8K |
| Two Sigma Securities, LLC | 0.00% | New | 36,248 | $7K |
| Citigroup Inc. | 0.00% | New | 34,051 | $7K |
| StoneX Group Inc. | 0.00% | New | 18,951 | $4K |
| Sassicaia Capital Advisers LLC | 0.00% | New | 15,977 | $3K |
| Composition Wealth, LLC | 0.00% | New | 10,000 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -2.8% | 2,393 | $459 |
| Bank of America Corp. | 0.00% | Add +250.0% | 378 | $72 |
| Jones Financial Companies LLLP | 0.00% | New | 188 | $40 |
| Wells Fargo & Company | 0.00% | No change | 154 | $30 |
| Osaic Holdings, Inc. | 0.00% | No change | 2 | $0 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.